New FDA Approved App Could Be The Next Big Thing In Diabetes Management
Over 3.3 million African Americans in the United States have diabetes. Ninety percent of these individuals have type 2 diabetes and are often treated with basal insulin—used to control blood glucose levels between meals and overnight.
According to the American Diabetes Association’s (ADA) 2016 Standards of Care, teaching patients with type 2 diabetes how to self-manage their insulin dose based on blood glucose levels improves glucose control. However, more than half of individuals with type 2 diabetes treated with basal insulin do not meet the recommended targets for blood glucose control. Major contributing factors include challenges with insulin initiation and dose adjustment by patients and health care professionals.
Voluntis, which makes companion software for medical devices, has received FDA clearance for Insulia®, the first of it’s kind app for the management of type 2 diabetes. With the FDA approval of Insulia insulin dosing and adjustment could be a lot easier.
Insulia is a prescription-only medical device that provides patients with insulin dose recommendations and educational coaching messages in response to blood glucose values and other diabetes-related data. To ensure optimal individualized treatment Insulia supports a wide variety of treatment plan configurations and evidence-based insulin adjustment recommendations found in the ADA 2016 Standards of Care and used in routine clinical practice.